Stock 600613 SHANGHAI SHENQI PHARMACEUTICAL INVESTMENT MANAGEMENT CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

Equities

600613

CNE000000453

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
6.53 CNY +1.08% Intraday chart for Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. +8.83% -14.19%
Apr. 29 Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 29 Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,657 3,770 2,500 3,291 4,220 3,902
Enterprise Value (EV) 1 2,487 3,620 2,366 3,110 3,850 3,419
P/E ratio 24.6 x 45.1 x -7.66 x 49.4 x 91.4 x 69.2 x
Yield - - - 1.56% 1.22% -
Capitalization / Revenue 1.43 x 1.96 x 1.37 x 1.43 x 1.77 x 1.67 x
EV / Revenue 1.34 x 1.88 x 1.3 x 1.35 x 1.61 x 1.46 x
EV / EBITDA 14.8 x 17.3 x -37.4 x 21.8 x 22.9 x 17.3 x
EV / FCF 41.8 x 12.9 x 11.7 x 54.1 x 16.3 x 26.1 x
FCF Yield 2.39% 7.77% 8.51% 1.85% 6.13% 3.83%
Price to Book 1.03 x 1.47 x 1.15 x 1.46 x 1.89 x 1.38 x
Nbr of stocks (in thousands) 534,072 534,072 534,072 534,072 534,072 534,072
Reference price 2 4.910 7.220 4.900 6.420 8.230 7.610
Announcement Date 4/29/19 4/29/20 4/29/21 4/29/22 4/28/23 4/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,853 1,928 1,819 2,303 2,389 2,341
EBITDA 1 168.3 209.6 -63.21 142.4 167.9 197.7
EBIT 1 120.7 154.4 -111.6 90.69 85.79 116.5
Operating Margin 6.51% 8.01% -6.13% 3.94% 3.59% 4.98%
Earnings before Tax (EBT) 1 125 108.3 -340.3 99.6 63.23 83.41
Net income 1 106.1 83.97 -341.2 69.62 48.48 57
Net margin 5.73% 4.36% -18.76% 3.02% 2.03% 2.43%
EPS 2 0.2000 0.1600 -0.6400 0.1300 0.0900 0.1100
Free Cash Flow 1 59.48 281.3 201.4 57.52 236 130.9
FCF margin 3.21% 14.59% 11.07% 2.5% 9.88% 5.59%
FCF Conversion (EBITDA) 35.34% 134.16% - 40.38% 140.56% 66.19%
FCF Conversion (Net income) 56.06% 334.92% - 82.61% 486.89% 229.58%
Dividend per Share - - - 0.1000 0.1000 -
Announcement Date 4/29/19 4/29/20 4/29/21 4/29/22 4/28/23 4/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 170 151 134 182 371 483
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 59.5 281 201 57.5 236 131
ROE (net income / shareholders' equity) 3.84% 3.06% -14.2% 2.88% 2.01% 2.45%
ROA (Net income/ Total Assets) 2.42% 2.89% -2.1% 1.81% 1.64% 2.19%
Assets 1 4,376 2,907 16,280 3,837 2,952 2,607
Book Value Per Share 2 4.760 4.900 4.260 4.390 4.360 5.510
Cash Flow per Share 2 0.3900 1.120 0.9000 0.9200 1.230 1.690
Capex 1 110 77 96.3 86 26.6 24.5
Capex / Sales 5.95% 3.99% 5.29% 3.73% 1.12% 1.05%
Announcement Date 4/29/19 4/29/20 4/29/21 4/29/22 4/28/23 4/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANGHAI SHENQI PHARMACEUTICAL INVESTMENT MANAGEMENT CO., LTD. Stock Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
-14.19% 466M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.30% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.36% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.61% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.39% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600613 Stock
  4. Financials Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.